News

Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

TORONTO, ON / ACCESSWIRE / February 6, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

2 years ago

Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

2 years ago

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer…

2 years ago

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that…

2 years ago

GRANT OF PERFORMANCE SHARE UNITS

Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive…

2 years ago

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Bria-Pros+ Activates Multiple Immune Cell Types Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified…

2 years ago

Revolutionary AI-Driven Medtech Platform Changes the Way Patients Receive Quality Healthcare in the UK

LONDON, UK / ACCESSWIRE / February 6, 2024 / Access to efficient and convenient healthcare is vital in order to…

2 years ago

AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / February 6, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

2 years ago

IRLAB’s Pioneering Phase IIb Study with Pirepemat – React-PD – Provides New Insights in Specific Parkinson’s Patient Population and Enables a Data Driven Prediction of Study Timelines

GOTHENBURG, SWEDEN / ACCESSWIRE / February 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 6, 2024 - IRLAB Therapeutics…

2 years ago

Delota Corp. Completes Debt Settlements

Vaughan, Ontario--(Newsfile Corp. - February 5, 2024) - Delota Corp. (CSE: LOTA) ("Delota" or the "Company") is pleased to announce…

2 years ago